Stock COLL COLLEGIUM PHARMACEUTICAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Collegium Pharmaceutical, Inc.

Equities

COLL

US19459J1043

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
36.42 USD +1.62% Intraday chart for Collegium Pharmaceutical, Inc. +4.54% +18.32%
04-11 Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes MT
02-26 Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes
Collegium Pharmaceutical's Q4 Adjusted Earnings, Revenue Increase
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
MORNING BRIEFING - USA/Asien
Collegium Pharmaceutical Expects Net Product Revenue of up to $595 Million in 2024
Collegium Pharmaceutical, Inc. announces an Equity Buyback for $150 million worth of its shares.
Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year 2024
Collegium Pharmaceutical, Inc. authorizes a Buyback Plan.
Collegium Pharmaceutical Insider Sold Shares Worth $2,075,086, According to a Recent SEC Filing
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023
Collegium Pharmaceutical Gets US New Patient Population Exclusivity Extension for Nucynta Analgesic, From 2025 to 2026
Collegium Pharmaceutical, Inc. Announces Extension of Nucynta Regulatory Exclusivity Through July 2026
Collegium Pharmaceutical Launches $50 Million Accelerated Share Buyback Program
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Year 2023
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Insider Sell: Collegium Pharmaceutical
Insider Sell: Collegium Pharmaceutical
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COLL Stock
  4. News Collegium Pharmaceutical, Inc.
  5. Other languages